31
Participants
Start Date
August 31, 2009
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
IXAZOMIB
Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
Cornell University, New York
Thomas Jefferson University, Philadelphia
University of Wisconsin Madison, Madison
Kansas University Medical Center, Westwood
Rocky Mountain Cancer Center, Denver
Tower Cancer Research Center, Beverly Hills
Jewish General Hospital, Montreal
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY